The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma

Detalhes bibliográficos
Autor(a) principal: Maiolino,Angelo
Data de Publicação: 2009
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000800009
Resumo: Major progress was obtained over the last ten years in the treatment of multiple myeloma (MM). High dose chemotherapy with autologous stem cell transplantation (ASCT) and new drugs such as thalidomide, lenalidomide and bortezomib have completely changed the scenario of MM treatment. ASCT has become the mainstay of MM treatment for patients up to 65 years old. This strategy has been tested in randomized clinical trials which proved that ASCT can improve overall survival of MM patients. Unfortunately, the great majority of these patients will relapse in a few years after ASCT. Strategies of maintenance have been developed trying to improve the results of ASCT. Thalidomide has been tested in this setting in at least 4 randomized clinical trials with a significant impact on response rate, and event free and overall survival.l.
id ABHHTC-1_c50ef77c850ea5a9e53bca1122840f6c
oai_identifier_str oai:scielo:S1516-84842009000800009
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myelomaMultiple myelomathalidomideautologous stem cell transplantationMajor progress was obtained over the last ten years in the treatment of multiple myeloma (MM). High dose chemotherapy with autologous stem cell transplantation (ASCT) and new drugs such as thalidomide, lenalidomide and bortezomib have completely changed the scenario of MM treatment. ASCT has become the mainstay of MM treatment for patients up to 65 years old. This strategy has been tested in randomized clinical trials which proved that ASCT can improve overall survival of MM patients. Unfortunately, the great majority of these patients will relapse in a few years after ASCT. Strategies of maintenance have been developed trying to improve the results of ASCT. Thalidomide has been tested in this setting in at least 4 randomized clinical trials with a significant impact on response rate, and event free and overall survival.l.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2009-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000800009Revista Brasileira de Hematologia e Hemoterapia v.31 suppl.2 2009reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1590/S1516-84842009000800009info:eu-repo/semantics/openAccessMaiolino,Angeloeng2009-09-29T00:00:00Zoai:scielo:S1516-84842009000800009Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2009-09-29T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
title The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
spellingShingle The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
Maiolino,Angelo
Multiple myeloma
thalidomide
autologous stem cell transplantation
title_short The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
title_full The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
title_fullStr The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
title_full_unstemmed The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
title_sort The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
author Maiolino,Angelo
author_facet Maiolino,Angelo
author_role author
dc.contributor.author.fl_str_mv Maiolino,Angelo
dc.subject.por.fl_str_mv Multiple myeloma
thalidomide
autologous stem cell transplantation
topic Multiple myeloma
thalidomide
autologous stem cell transplantation
description Major progress was obtained over the last ten years in the treatment of multiple myeloma (MM). High dose chemotherapy with autologous stem cell transplantation (ASCT) and new drugs such as thalidomide, lenalidomide and bortezomib have completely changed the scenario of MM treatment. ASCT has become the mainstay of MM treatment for patients up to 65 years old. This strategy has been tested in randomized clinical trials which proved that ASCT can improve overall survival of MM patients. Unfortunately, the great majority of these patients will relapse in a few years after ASCT. Strategies of maintenance have been developed trying to improve the results of ASCT. Thalidomide has been tested in this setting in at least 4 randomized clinical trials with a significant impact on response rate, and event free and overall survival.l.
publishDate 2009
dc.date.none.fl_str_mv 2009-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000800009
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000800009
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-84842009000800009
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.31 suppl.2 2009
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213109813215232

Registros relacionados